DE69231930D1 - Verfahren zur behandlung von erkrankungen motorischer neuronen durch mitglieder der bdnf/nt-3/ngf-familie - Google Patents

Verfahren zur behandlung von erkrankungen motorischer neuronen durch mitglieder der bdnf/nt-3/ngf-familie

Info

Publication number
DE69231930D1
DE69231930D1 DE69231930T DE69231930T DE69231930D1 DE 69231930 D1 DE69231930 D1 DE 69231930D1 DE 69231930 T DE69231930 T DE 69231930T DE 69231930 T DE69231930 T DE 69231930T DE 69231930 D1 DE69231930 D1 DE 69231930D1
Authority
DE
Germany
Prior art keywords
bdnf
members
treating diseases
ngf family
motor neurones
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69231930T
Other languages
English (en)
Other versions
DE69231930T2 (de
Inventor
Vivien Wong
Czeslaw Radziejewski
Peter Distefano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften eV, Regeneron Pharmaceuticals Inc filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Publication of DE69231930D1 publication Critical patent/DE69231930D1/de
Application granted granted Critical
Publication of DE69231930T2 publication Critical patent/DE69231930T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE69231930T 1991-07-10 1992-05-19 Verfahren zur behandlung von erkrankungen motorischer neuronen durch mitglieder der bdnf/nt-3/ngf-familie Expired - Lifetime DE69231930T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72770491A 1991-07-10 1991-07-10
PCT/US1992/004228 WO1993001300A1 (en) 1991-07-10 1992-05-19 Methods of treatment of motor neuron diseases using members of the bdnf/nt-3/ngf family of molecules

Publications (2)

Publication Number Publication Date
DE69231930D1 true DE69231930D1 (de) 2001-08-16
DE69231930T2 DE69231930T2 (de) 2002-04-11

Family

ID=24923677

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69231930T Expired - Lifetime DE69231930T2 (de) 1991-07-10 1992-05-19 Verfahren zur behandlung von erkrankungen motorischer neuronen durch mitglieder der bdnf/nt-3/ngf-familie

Country Status (20)

Country Link
EP (2) EP0755682A1 (de)
JP (1) JPH06509094A (de)
CN (1) CN1065768C (de)
AT (1) ATE202939T1 (de)
AU (2) AU675409B2 (de)
CA (1) CA2113083A1 (de)
DE (1) DE69231930T2 (de)
DK (1) DK0593516T3 (de)
ES (1) ES2157903T3 (de)
FI (1) FI940098A (de)
GR (1) GR3036776T3 (de)
HU (1) HUT70275A (de)
IE (1) IE921602A1 (de)
IL (1) IL101928A0 (de)
NO (1) NO940084L (de)
PT (1) PT100501A (de)
RU (1) RU94016525A (de)
SK (1) SK2694A3 (de)
WO (1) WO1993001300A1 (de)
ZA (1) ZA923639B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07509600A (ja) * 1992-06-12 1995-10-26 リジェネロン　ファーマシューティカルズ，インコーポレーテッド ニューロトロフィン−４発現に基づく治療および診断法
FR2717496B1 (fr) * 1994-03-18 1996-04-12 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
CN1112215C (zh) * 1999-12-28 2003-06-25 潘晓东 神经生长因子在治疗有机溶剂中毒性周围神经病中的用途
CA2408255A1 (en) 2000-05-05 2001-11-15 Marie T. Filbin Methods for stimulating nervous system regeneration and repair by regulating arginase 1 and polyamine synthesis
US7691629B2 (en) * 2004-11-17 2010-04-06 Neuralstem, Inc. Transplantation of human neural cells for treatment of neurodegenerative conditions
WO2008156418A1 (en) * 2007-06-19 2008-12-24 Astrazeneca Ab A method for screening or diagnosis of postpolio syndrome and fibromyalgia
PT2187964E (pt) * 2007-08-10 2015-01-14 Regeneron Pharma Anticorpos humanos de elevada afinidade para o factor de crescimento neural humano
WO2014111525A2 (en) 2013-01-18 2014-07-24 Anaxomics Biotech, Sl New combination therapies for treating nervous system diseases
WO2016210325A1 (en) 2015-06-26 2016-12-29 C.R. Bard, Inc. Connector interface for ecg-based catheter positioning system
WO2023164311A2 (en) * 2022-02-28 2023-08-31 Bioincept, Llc Compositions and methods of treating amyotrophic lateral sclerosis (als) and related disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923696A (en) * 1987-05-04 1990-05-08 Baylor College Of Medicine Method to prepare a neurotrophic composition
GR1000980B (el) * 1989-08-30 1993-03-31 Max Planck Gesellschaft Νευροτροφινη-3,ενας νεος neυροτροφικος παραγοντας που σχετιζεται με τον παραγοντα αναπτυξης νευρων και τον νευροτροφικο παραγοντα που προερχεται απο τον εγκεφαλο.
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
IE903130A1 (en) * 1989-09-15 1991-03-27 Regeneron Pharma Ciliary neurotrophic factor

Also Published As

Publication number Publication date
WO1993001300A1 (en) 1993-01-21
EP0593516A1 (de) 1994-04-27
GR3036776T3 (en) 2002-01-31
DK0593516T3 (da) 2001-09-17
RU94016525A (ru) 1996-06-10
SK2694A3 (en) 1995-02-08
CN1065768C (zh) 2001-05-16
ATE202939T1 (de) 2001-07-15
NO940084L (no) 1994-03-08
AU675409B2 (en) 1997-02-06
CN1071585A (zh) 1993-05-05
CA2113083A1 (en) 1993-01-21
IL101928A0 (en) 1992-12-30
HU9400063D0 (en) 1994-06-28
NO940084D0 (no) 1994-01-10
AU7067696A (en) 1997-01-16
DE69231930T2 (de) 2002-04-11
PT100501A (pt) 1993-09-30
ZA923639B (en) 1993-02-24
EP0755682A1 (de) 1997-01-29
AU2009592A (en) 1993-02-11
ES2157903T3 (es) 2001-09-01
EP0593516A4 (de) 1995-01-18
JPH06509094A (ja) 1994-10-13
FI940098A (fi) 1994-03-10
HUT70275A (en) 1995-09-28
EP0593516B1 (de) 2001-07-11
IE921602A1 (en) 1993-01-13
FI940098A0 (fi) 1994-01-10

Similar Documents

Publication Publication Date Title
DE69231930T2 (de) Verfahren zur behandlung von erkrankungen motorischer neuronen durch mitglieder der bdnf/nt-3/ngf-familie
DE69634301D1 (de) Methode zur behandlung von alzheimer mit einem von einer gliazelllinie stammenden neurotrophen protein (gdnf)
DE69428130T2 (de) Verwendung von bcl-2 zur herstellung von arzneimitteln zur therapeutischen behandlung und verhinderung von krankheiten
DE69524679D1 (de) Verwendung Rapamycin zur Herstellung eines Medikaments für die Verbeugung und Behandlung von hyperproliferativen Gefässerkrankheiten, eventuell in Kombination mit Mycophenolsäure
DE58906894D1 (de) Einrichtung zur diagnostik und behandlung von nasenerkrankungen.
ATE178616T1 (de) Verfahren zur herstellung von biologisch aktivem protein (z.b. tgf)
DE69328981D1 (de) Verfahren zur Behandlung von hyperproliferaktiven Gefässerkrankungen unter Verwendung von Rapamycin, eventuell in Kombination mit Mykophenolsäure
DE3686361T2 (de) Verwendung von bismuth zur herstellung von medikamenten zur behandlung von magen-darmstoerungen, die von campylobacter polyridis verursacht sind.
ATE196082T1 (de) Stickstoffoxyd abgebendes präparat zur behandlung von analen erkrankungen
ATE121938T1 (de) Hemmung von muskelschwund und proteinabbau von muskeln bei säugetieren durch tetrazyklines.
EP0219524A1 (de) Behandlung des atemunwohlseinsyndroms bei erwachsenen.
DE69121561T2 (de) Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht
FI943028A0 (fi) Happoa kestävä FGF-koostumus ja menetelmä ruoansulatuskanavassa esiintyvien, haavaumia aiheuttavien sairauksien hoitamiseksi
DE3770465D1 (de) Verwendung von zinn-protoporphyrin und zinn-mesoporphyrin zur herstellung eines arzneimittels fuer die behandlung von psoriasis.
DE69635213D1 (de) Verwendung von Olanzapin zur Behandlung von mentalen Erkrankungen verursacht durch zerebrovaskuläre Erkrankungen
ATE79254T1 (de) Die verwendung von d-fenfluramin zur herstellung von arzneimitteln, zur behandlung von depressionen.
ATE122100T1 (de) Humaner monoklonaler antikörper und diesen enthaltende arzneimittelzusammensetzung zur behandlung von pseudomonasinfektionen.
DE69220939D1 (de) Gegengift immunsera
ATE69949T1 (de) Liposomen mit inhalativen allergenen zur behandlung von allergien, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
ATE84666T1 (de) Sichere pestizide harzzusammensetzungen zur bekaempfung von bodenbuertigen krankheiten und verfahren zu deren herstellung.
ATE101054T1 (de) Einrichtung zur diagnostik und behandlung von nasenerkrankungen.
CH572346A5 (en) Electrotherapeutical appts. with electrodes applied to patient - indicator lamps connected with electrode give visual control
DE69218544T2 (de) Verwendung von BMY 14802 zur Behandlung von Angstzuständen bei Patienten mit Benzodiazepin-Entzugserscheinungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: REGENERON PHARMACEUTICALS, INC., TARRYTOWN, N.Y.,